Purespring appoints Fredrik Erlandsson as Chief Medical Officer and Peter Mulcahy as Chief People Officer

London— 6 September 2023

Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, has appointed Fredrik Erlandson as Chief Medical Officer and Peter Mulcahy as Chief People Officer.

These two key additional appointments complete Purespring’s leadership team, filling critical medical and enabling functions, with Fredrik leading the clinical development of Purespring’s current and future pipeline and Peter championing culture, talent, purpose, and growth at the Company.

Purespring recently appointed Sachin Kelkar as Chief Financial Officer as it confirmed the appointment of Julian Hanak as Chief Executive Officer on a permanent basis.

Fredrik Erlandsson is an experienced developer of novel nephrology drugs and has worked in all phases of development, from target identification through to post product launch phase IV studies, and in medical affairs at both large pharma and biotech. Before joining Purespring, Fredrik served as Head Global Clinical Development at CSL Vifor. He has previously held positions within the clinical development teams at AstraZeneca, Bayer, and Antisoma. Fredrik has contributed to multiple drug approvals, including Filspari, Korsuva/Kapruvia, and Tavneos. He has a medical degree and a PhD from the Karolinska Institute in Stockholm, Sweden.

Peter Mulcahy brings significant leadership experience and expertise in human capital and people strategy, having spent the past 11 years of his career at GlaxoSmithKline, most recently as Vice President in Human Resources. He has extensive expertise across all aspects of HR including talent management, organisation development and designing and leading people strategies for business transformation and M&A.

Julian Hanak, Chief Executive Officer of Purespring, commented on the appointments:

“Purespring was created as a fully integrated company at the outset with all the building blocks in place to move rapidly through clinical validation and transform the treatment of kidney diseases as rapidly as possible. Fredrik and Peter both bring unique skills in, respectively, clinical development and talent and organisational design, critical to a Company at our stage of development. This means we now have the key functions in place to bring our potentially life-changing treatments through clinical development and support the organisation as it scales.”

Fredrik Erlandsson, Chief Medical Officer of Purespring, said

“Having worked in nephrology for much of my career, I’m very aware how poorly served people with kidney disease are and the huge unmet need. Purespring has an opportunity to redefine this field of medicine with its targeted approach to the podocyte, and I’m really excited to start working with Julian and the rest of this talented team.”

Peter Mulcahy, Chief People Officer of Purespring, said

“It’s so important, as a business moves from launch through to a clinical phase, to provide the right organisational HR partnership and, importantly, to build a great culture and to get the best out of teams. The Company has seen considerable growth to date, with incredible talent coming on board, and this owes to the excellent culture and leadership already in place. I’m really looking forward to working with the team during this next phase of development.”

About Purespring

Purespring Therapeutics is a clinical-stage precision nephrology company leading the development of targeted, first-in-class genetic therapies to preserve kidney function. Through its proprietary GlomThera™ platform, Purespring is able to deliver genetic therapies directly to the podocyte, offering a novel approach to the treatment of kidney diseases.

Purespring’s pipeline targets multiple renal indications with significant unmet medical need. The Company’s lead programme, PS-002, offers a highly differentiated approach for patients with IgA nephropathy (IgAN). By precisely targeting the site of disease, Purespring aims to transform the trajectory of kidney disease so patients can live fuller, healthier lives.

Purespring is backed by leading biotech investors, including Syncona Limited, Sofinnova Partners, Gilde Healthcare, Forbion, and the British Business Bank and has raised £115m ($150m) to date.

For more information please visit: purespringtx.com and follow us on LinkedIn.